CNS PharmaceuticalsCNSP
13F holders, Q2 2025 (June 30)10holders +3
5new positions
2sold out
$0.82avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding CNS Pharmaceuticals Inc. (CNSP) in their 13F filings, up 3 from Q1 2025. 5 opened new positions and 2 sold out. The largest holders were Armistice Capital, LLC ($335K), UBS Group AG ($26K) and Virtu Financial LLC ($19K).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H409
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $390K |
| Exits | 2 | $15K |
All 13F filers, Q1 2025 → Q2 2025: 483,507 shares bought and 11,356 shares sold, net +472,151 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Armistice Capital, LLC | 0.01% | New | 406,000 | $335K |
| UBS Group AG | 0.00% | Add +33.9% | 32,103 | $26K |
| Virtu Financial LLC | 0.00% | New | 23,348 | $19K |
| Geode Capital Management, LLC | 0.00% | New | 17,871 | $15K |
| Two Sigma Securities, LLC | 0.00% | New | 15,633 | $13K |
| HRT Financial LP | 0.00% | New | 10,863 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +31.8% | 6,738 | $6K |
| Barrett & Company, Inc. | 0.00% | No change | 100 | $83 |
| Bank of America Corp. | 0.00% | Add +444.4% | 49 | $40 |
| MAI Capital Management | 0.00% | No change | 40 | $33 |
"% of holder's portfolio" is CNSP's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.